Production of beta-lactamases, the enzymes that degrade beta-lactam antibiotics, is the most widespread and threatening mechanism of antibiotic resistance. In the past, extensive research has focused on the structure, function, and ecology of beta-lactamases while limited efforts were placed on the regulatory mechanisms of beta-lactamases. Recently, increasing evidence demonstrate a direct link between beta-lactamase induction and cell wall metabolism in Gram-negative bacteria. Specifically, expression of beta-lactamase could be induced by the liberated murein fragments, such as muropeptides. This article summarizes current knowledge on cell wall metabolism, beta-lactam antibiotics, and beta-lactamases. In particular, we comprehensively reviewed recent studies on the beta-lactamase induction by muropeptides via two major molecular mechanisms (the AmpG–AmpR–AmpC pathway and BlrAB-like two-component regulatory system) in Gram-negative bacteria. The signaling pathways for beta-lactamase induction offer a broad array of promising targets for the discovery of new antibacterial drugs used for combination therapies. Therefore, to develop effective mitigation strategies against the widespread beta-lactam resistance, examination of the molecular basis of beta-lactamase induction by cell wall fragment is highly warranted.

The Gram-negative bacterium Campylobacter is the most common bacterial cause of human gastroenteritis in the United States and many industrialized countries. Poultry, particularly chickens, is considered a major source of human campylobacteriosis. Thus, on-farm control of Campylobacter in poultry would reduce the risk of human exposure to this pathogen and have a significant impact on food safety and public health. To date, three general strategies have been proposed to control Campylobacter in poultry at the farm level: (1) reduction of environmental exposure (biosecurity measures), (2) an increase in poultry's host resistance to reduce Campylobacter carriage in the gut (e.g., competitive exclusion, vaccination, and host genetics selection), and (3) the use of antimicrobial alternatives to reduce and even eliminate Campylobacter from colonized chickens (e.g., bacteriophage therapy and bacteriocin treatment). Except for biosecurity measures, the other intervention approaches are currently not commercially available and are still under development. This review is focused on two promising strategies—vaccination and bacteriocin treatment. In particular, we extensively review recent research aimed at discovering and characterizing potent anti-Campylobacter bacteriocins to reduce Campylobacter load at the primary production level in poultry.

CmeABC, a resistance-nodulation-division (RND) type of efflux pump, contributes to Campylobacter resistance to a broad spectrum of antimicrobial agents and is also essential for Campylobacter colonization of the animal intestinal tract by mediation of bile resistance. As one of the main systems for Campylobacter adaptation to different environments, CmeABC is likely subject to control by regulatory elements. We describe the identification of a transcriptional repressor for CmeABC. Insertional mutagenesis of cmeR , an open reading frame immediately upstream of the cmeABC operon, resulted in overexpression of cmeABC , as determined by transcriptional fusion (P _cmeABC-lacZ ) and immunoblotting with CmeABC-specific antibodies. Overexpression of the efflux pump was correlated with a moderate increase in the level of resistance of the cmeR mutant to several antimicrobials. In vitro, recombinant CmeR bound specifically to the promoter region of cmeABC , precisely, to the inverted repeat sequences in the cmeABC promoter. A single nucleotide deletion between the two half sites of the inverted repeat reduced the level of CmeR binding to the promoter sequence and resulted in overexpression of cmeABC . Together, these findings indicate that cmeR encodes a transcriptional repressor that directly interacts with the cmeABC promoter and modulates the expression of cmeABC . Mutation either in CmeR or in the inverted repeat impedes the repression and leads to enhanced production of the MDR efflux pump.

Antibiotic growth promoters (AGPs) have been used as feed additives to improve average daily weight gain and feed efficiency in food animals for more than five decades. However, use of AGPs is associated with the emergence of antibiotic-resistant human pathogens of animal origin, posing a significant threat to food safety and public health. Thus, development of novel alternatives to AGPs is important to mitigate antimicrobial resistance in foodborne pathogens. To achieve this goal, the mode of action of AGPs should be elucidated. In this study, the response of the chicken gut microbiota to AGPs was examined using two culture-independent approaches: phospholipid fatty acid (PLFA) biomarker analysis and 16S rDNA clone library sequencing. PLFA analysis showed that AGP tylosin treatment changed composition of the microbiota in various intestinal sites; however, total viable bacterial biomass in intestine was not affected by tylosin treatment. PLFA analysis also revealed an abundant viable fungal population in chicken microbiota. Eight 16S rDNA libraries (96 clones per library) were constructed using ileal samples from chickens that received either antibiotic-free or medicated feed. The 16S rDNA clone analysis of the growth-relevant samples showed the AGP treatment influenced the diversity of ileum microbiota in the chickens primarily in the Firmicutes division. In particular, Lactobacillus spp. populations in the ileum of AGP-treated chickens were significantly lower than those from chickens receiving antibiotic-free feed. Together, this study revealed novel features of the intestinal microbiota in response to AGP treatment and suggested approach to develop potential alternatives to AGPs for mitigation of antimicrobial resistance in foodborne pathogens.

Antibiotic growth promoters (AGPs) have been used as feed additives to improve average body weight gain and feed efficiency in food animals for more than 5 decades. However, there is a worldwide trend to limit AGP use to protect food safety and public health, which raises an urgent need to discover effective alternatives to AGPs. The growth-promoting effect of AGPs has been shown to be highly correlated with the decreased activity of intestinal bile salt hydrolase (BSH), an enzyme that is produced by various gut microflora and involved in host lipid metabolism. Thus, BSH inhibitors are likely promising feed additives to AGPs to improve animal growth performance. In this study, the genome ofLactobacillus salivariusNRRL B-30514, a BSH-producing strain isolated from chicken, was sequenced by a 454 GS FLX sequencer. A BSH gene identified by genome analysis was cloned and expressed in anEscherichia coliexpression system for enzymatic analyses. The BSH displayed efficient hydrolysis activity for both glycoconjugated and tauroconjugated bile salts, with slightly higher catalytic efficiencies (k_cat/K_m) on glycoconjugated bile salts. The optimal pH and temperature for the BSH activity were 5.5 and 41°C, respectively. Examination of a panel of dietary compounds using the purified BSH identified some potent BSH inhibitors, in which copper and zinc have been recently demonstrated to promote feed digestion and body weight gain in different food animals. In sum, this study identified and characterized a BSH with broad substrate specificity from a chickenL. salivariusstrain and established a solid platform for us to discover novel BSH inhibitors, the promising feed additives to replace AGPs for enhancing the productivity and sustainability of food animals.

Despite prevalent β-lactam resistance in Campylobacter jejuni, an important zoonotic enteric pathogen, the molecular basis of β-lactamase-mediated β-lactam resistance is still largely unknown. In particular, some C. jejuni strains that carry β-lactamase gene bla_OXA-61 (Cj0299) are still susceptible to β-lactams with undetected β-lactamase activity, suggesting bla_OXA-61 is subjected to regulation. The objective of this study was to determine the regulatory mechanism of β-lactamase in C. jejuni. An ampicillin-resistant derivative of C. jejuni NCTC 11168 was subjected to whole genome sequencing and comparative genomics analysis. Complementary molecular experiments were further performed to examine the identified regulatory mechanism of bla_OXA-61, which included complementation, promoter fusion assay, real-time RT–PCR, natural transformation using a defined PCR fragment, survey of clinical isolates and transcription start site mapping. A single nucleotide mutation (G → T transversion) upstream of bla_OXA-61 was identified in the ampicillin-resistant derivative of NCTC 11168. The role of the G → T point mutation in acquired β-lactam resistance through up-regulating the expression of bla_OXA-61 was confirmed by multiple molecular approaches. The G → T transversion in the bla_OXA-61 promoter was linked to high-level β-lactam resistance in C. jejuni isolates. Transcription start site mapping indicated that the G → T transversion restored the TATA box in the −10 region of bla_OXA-61. We demonstrated a novel genetic mechanism of β-lactamase regulation in C. jejuni in this study, which will provide insights into the regulation and evolution of β-lactam resistance in Campylobacter.